Evidence map›Paper›PMID 35883104›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers.

Nicole Gull, Michelle R Jones, Pei-Chen Peng, Simon G Coetzee, Tiago C Silva, Jasmine T Plummer, Alberto Luiz P Reyes, Brian D Davis, Stephanie S Chen, Kate Lawrenson and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. bioRxiv : the preprint server for biology · 2024
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Nicole Gull *Department of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Michelle R Jones *Department of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Pei-Chen Peng *Department of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Simon G CoetzeeDepartment of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Tiago C SilvaDivision of Biostatistics, Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, FL, 33101, USA.
Jasmine T PlummerDepartment of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Alberto Luiz P ReyesDepartment of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Brian D DavisDepartment of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Stephanie S ChenDepartment of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Kate LawrensonDepartment of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Jenny LesterWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Christine WalshWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Bobbie J RimelWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Andrew J LiWomen's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Ilana CassDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Hanover, NH, 03756, USA.
Yonatan BergDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, 91120, Jerusalem, Israel.
John-Paul B GovindavariDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Joanna K L RutgersDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Benjamin P BermanDepartment of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Beth Y Karlan *Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Simon A Gayther *Department of Biomedical Sciences, Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. simon.gayther@cshs.org.
Cedars-Sinai Medical Center · USDartmouth–Hitchcock Medical Center · USUniversity of Miami · US

Funding

Software Tools For Regulatory Analysis of Large Cancer Methylome DatasetsU01CA184826 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERMAN, BENJAMIN P · 2014 to 2016
$1.1M
Identifying new drivers of ovarian cancer from the non-coding genome by converging germline risk variants and somatic mutationsK99CA256519 · NCI · CEDARS-SINAI MEDICAL CENTER · PI PENG, PEI-CHEN · 2021 to 2022
$400k
NCI NIH HHS K99 CA256519NCI NIH HHS K99CA256519NCI NIH HHS U01 CA184826NIH HHS U01CA184826NIH/NCI R01CA211575Ovarian Cancer Research Alliance Liz Tilberis Early Career Award 599175Ovarian Cancer Research Alliance Program Project Development Award 373356Research Scholar's Grant from the American Cancer Society 134005
6 · The paper itself

Abstract

backgroundLittle is known about the role of global DNA methylation in recurrence and chemoresistance of high grade serous ovarian cancer (HGSOC).

methodsWe performed whole genome bisulfite sequencing and transcriptome sequencing in 62 primary and recurrent tumors from 28 patients with stage III/IV HGSOC, of which 11 patients carried germline, pathogenic BRCA1 and/or BRCA2 mutations.

resultsLandscapes of genome-wide methylation (on average 24.2 million CpGs per tumor) and transcriptomes in primary and recurrent tumors showed extensive heterogeneity between patients but were highly preserved in tumors from the same patient. We identified significant differences in the burden of differentially methylated regions (DMRs) in tumors from BRCA1/2 compared to non-BRCA1/2 carriers (mean 659 DMRs and 388 DMRs in paired comparisons respectively). We identified overexpression of immune pathways in BRCA1/2 carriers compared to non-carriers, implicating an increased immune response in improved survival (P = 0.006) in these BRCA1/2 carriers.

conclusionThese findings indicate methylome and gene expression programs established in the primary tumor are conserved throughout disease progression, even after extensive chemotherapy treatment, and that changes in methylation and gene expression are unlikely to serve as drivers for chemoresistance in HGSOC.

Indexed as

DNA MethylationOvarian NeoplasmsDrug Resistance, NeoplasmFemaleHumansNeoplasm Recurrence, LocalTranscriptomeChemoresistanceComputational methodsEpigeneticsHigh grade serous ovarian cancerMethylationTranslational researchWhole genome bisulfite sequencing

Identifiers

PMID35883104
PMCPMC9327231
OpenAlexW4288178086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.